Sasha Farrell May 7, 2018

Less than 50% of women who were diagnosed with ovarian cancer can survive for 5 years, as the treatment methods are old and inefficient. But with new treatments on trial, a new ray of hope has emerged.

A revolutionary new treatment is undergoing the safety trail in Australia to stop the development of ovarian cancer by eliminating the stem cell of cancer. As per the study, merely 44% of women diagnosed with this sort cancer can live more 5 years.

Jane Hill, CEO, Ovarian cancer Australia, said, a shortfall of research funding is the reason that the treatment methods are same as 1970s such as chemotherapy and surgery.

In general, 8 out of 10 women respond to chemotherapy and surgical treatment but more than 50% of them face relapse of the treatment in just 2 years and then their cancerous cells develop drug-resistant characteristic.

A new medication known as PARP inhibitors launched recently shows an increase in the survival period of patients; though, it is not full-proof. At present, Australian scientists and Kazia, Pharmaceutical Company in Australia, are working in collaboration to develop new medication called Cantrixil.

Jim Coward, Oncologist, Icon cancer Care, head of the trial stated, there are some stem cells of cancer which do not get eliminated at the time of chemotherapy, stay at hibernate, and then get active and start growing again after some time.

“Cantrixil is believed to be an effective treatment for individuals facing recurrent events of ovarian cancer, as it has proved in the lab tests of being able to the elimination of cancer-initiating cells which are the main cause of origin, relapsing and metastasizing of cancer.”

The new treatment trails are going on in Adelaide, Brisbane, and Sydney. Women can visit the official website, www.cancertraial.gov.au, to take part in the trails. Prof. Coward said he was very pleased to offer the consultation to people from all around the nation.

Sasha Farrell

Sasha Farrell is a privileged and versatile content writer and editor in the domains of Pharma, Health, and Medical. Before getting into the writing world, Sasha was working as an STM editor for few renowned authors and publications, which gave head-start to rifle through the Pharma, Health, and Medical Innovations.

Leave a comment.

Your email address will not be published. Required fields are marked*